US2009291998A1PendingUtilityA1
Eponemycin and epoxomicin analogs and uses thereof
Est. expiryJan 8, 2022(expired)· nominal 20-yr term from priority
Inventors:Sergei AgoulnikKozo AkasakaFrancis G. FangJean-Christophe HarmangeLynn HawkinsYimin JiangCharles W. JohannesXiang LiPamela McguinnessErin A. MurphyShawn SchillerMary VermeulenJiayi Wu
A61P 37/00A61P 43/00A61P 31/18A61P 35/02A61P 35/00C07D 405/12C07F 9/65502C07D 209/48A61P 29/00A61K 38/00C07F 5/025C07K 5/06139C07D 407/12C07D 303/36
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides compounds having formula (1): wherein R 1 -R 6 , A, J, D, A, G, Q, w, x, y, and z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of cancer and/or inflammatory disorders, and more generally as proteasome inhibitors.
Claims
exact text as granted — not AI-modified1 . A compound having the structure (I):
and pharmaceutically acceptable derivatives thereof;
wherein each occurrence of E or D is independently absent, CR A , CR A R B , C═O, O, S, NR A , or N, wherein each occurrence of R A and R B is independently hydrogen, a protecting group, or an aliphatic, alicyclic, heteroaliphatic heteroalicyclic, aryl or heteroaryl moiety;
D and E are linked by a single or double bond as valency permits;
z is 0, 1, 2, 3, 4, 5 or 6;
R 1 , R 2 , R 3 and R 4 are each independently hydrogen, halogen, —CN, —OR C , —SR C , —NR C R D , —(C═O)R C or an aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl or heteroaryl moiety, wherein each occurrence of R C and R D is independently hydrogen, a protecting group, or an aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl or heteroaryl moiety, or R C and R D , taken together, form a heteroalicyclic or heteroaryl moiety; or wherein any two adjacent groups R 1 , R 2 , R 3 and R 4 , taken together, form an alicyclic or heteroalicyclic moiety, or an aryl or heteroaryl moiety;
R 5 and R 6 are each independently an aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl or heteroaryl moiety; and Q is an epoxycarbonyl moiety having the structure:
wherein R Q1 is hydrogen an aliphatic, alicyclic heteroaliphatic, heteroalicyclic aryl or heteroaryl moiety, an oxygen protecting group or a prodrug moiety.
2 - 62 . (canceled)
63 . A pharmaceutical composition comprising a compound of claim 1 ; and
a pharmaceutically acceptable carrier or diluent, and optionally further comprising an additional therapeutic agent.
64 - 67 . (canceled)
68 . A method for treating cancer comprising:
administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 ; and optionally further administering an additional therapeutic agent.
69 - 70 . (canceled)
71 . The compound of claim 1 , wherein the compound has the structure:
72 . The compound of claim 71 , wherein the compound has the structure:
73 . The compound of claim 1 , wherein the compound has the structure:
wherein R 5a is hydrogen, an aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl or heteroaryl moiety, an oxygen protecting group or a prodrug moiety.
74 . The compound of claim 1 , wherein the compound has the structure:
wherein AR is an aryl or heteroaryl moiety.
75 . The compound of claim 1 , wherein the compound has the structure:
wherein R 5a and R 5b are each independently hydrogen, a nitrogen protecting group, an aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl or heteroaryl moiety, or a prodrug, or R 5a and R 5b , taken together, form a heteroalicyclic or heteroaryl moiety.
76 . The compound of claim 1 , wherein the compound has the structure:
77 . The compound of claim 1 , wherein the compound has the structure:
78 . The compound of claim 1 , wherein the compound has the structure:
wherein R 5a is hydrogen, an aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl or heteroaryl moiety, an oxygen protecting group or a prodrug moiety.
79 . The compound of claim 1 , wherein the compound has the structure:
wherein AR is an aryl or heteroaryl moiety.
80 . The compound of claim 1 , wherein the compound has the structure:
wherein R 5a and R 5b are each independently hydrogen, a nitrogen protecting group, an aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl or heteroaryl moiety, or a prodrug, or R 5 , and R 5b , taken together, form a heteroalicyclic or heteroaryl moiety.
81 . The compound of claim 1 , wherein the compound has the structure:
82 . The compound of claim 1 , wherein the compound has the structure:
wherein R 5a is hydrogen, an aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl or heteroaryl moiety, an oxygen protecting group or a prodrug moiety.
83 . The compound of clam 1 , wherein the compound has the structure:
wherein AR is an aryl or heteroaryl moiety.
84 . The compound of claim 1 , wherein the compound has the structure:
wherein R 5a and R 5b are each independently hydrogen, a nitrogen protecting group, an aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl or heteroaryl moiety, or a prodrug, or R 5a and R 5b , taken together, form a heteroalicyclic or heteroaryl moiety.
85 . The compound of claim 1 , wherein R 1 , R 2 , R 3 and R 4 are each independently hydrogen, halogen, protected or unprotected hydroxyl, protected or unprotected thiol, protected or unprotected amino, alkyl, alkoxy, thioalkyl, mono- or di-substituted alkylamino, or wherein any two adjacent groups R 1 , R 2 , R 3 or R 4 , taken together are a cycloalkyl, heterocycloalkyl, aryl or heteroaryl moiety,
whereby each of the alkyl moieties is independently substituted or unsubstituted, linear or branched, cyclic or acyclic, and each of the aryl and heteroaryl moieties is independently substituted or unsubstituted.
86 . The compound of claim 1 , wherein R 5 is alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, C 1-6 OR 5a , C 1-6 NR 5a R 5b , aryl or heteroaryl; wherein R 5a and R 5b are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, —C(NH 2 )═N(NO 2 ), —C(═O)OR 5s , —C(═O)R 5 , or a protecting group; wherein R 5c is hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl.
87 . The compound of claim 1 , wherein R 5 is alkyl, cycloalkyl, —CH 2 OR 5a , —CH 2 NR 5a R 5b , —CH 2 aryl or —CH 2 heteroaryl; wherein R 5 , and R 5b are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, —C(NH 2 )═N(NO 2 ), —C(═O)OR 5c , —C(═O)R 5c or a protecting group; wherein R 5c is hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl.
88 . The compound of claim 1 , wherein R 5 is alkyl, cycloalkyl, CH 2 OR 5a , CH 2 NR 5a R 5b or substituted or unsubstituted —CH 2 Ph; wherein R 5 , and R 5b are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, —C(NH 2 )═N(NO 2 ), —C(═O)OR 5c , —C(═O)R 5 , or a protecting group; wherein R 5c is hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl.
89 . The compound of claim 1 , wherein R 5 is —CH 2 OH or benzyl.
90 . The compound of claim 1 , wherein R 6 is alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl or heteroaryl.
91 . The compound of claim 1 , wherein R 6 is lower alkyl or aryl.
92 . The compound of claim 1 , wherein R 6 is —CH 2 CH(CH 3 ) 2 .
93 . The compound of claim 1 or 71 , wherein Q has the structure:
94 . The compound of claim 1 or 71 , wherein Q has the structure:
95 . The compound of claim 1 , wherein the compound is selected from the group consisting of the following compounds:
96 . The compound of claim 1 , wherein the compound is
97 . The pharmaceutical of claim 63 wherein the compound is present in an amount effective to exert an antiproliferative and/or anticancer effect.
98 . The pharmaceutical of claim 63 wherein the compound and the additional therapeutic agent are present in an amount effective to exert an antiproliferative and/or anticancer effect.
99 . The pharmaceutical of claim 63 wherein the compound is present in an amount effective to exert an anti-inflammatory effect.
100 . The pharmaceutical of claim 63 wherein the compound and the additional therapeutic agent are present in an amount effective to exert an anti-inflammatory effect.
101 . The method of claim 68 , wherein the method is used to treat prostate, breast, colon, bladder, cervical, skin, testicular, kidney, ovarian, stomach, brain, liver, pancreatic or esophageal cancer or lymphoma, leukemia, or multiple myeloma.
102 . The method of claim 68 , wherein the cancer is a solid tumor.
103 . A compound having the structure:
and pharmaceutically acceptable derivatives thereof.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.